We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · January 27, 2021

Hepatocellular Lipid Reduction With Combined Exenatide and Dapagliflozin in T2DM

Diabetes, Obesity & Metabolism


Additional Info

Diabetes, Obesity & Metabolism
Combined EXENatide and DApagliflozin has no Additive Effects on Reduction of Hepatocellular Lipids Despite Better Glycemic Control in Patients With Type 2 Diabetes Mellitus Treated With Metformin – EXENDA, a 24 Week, Prospective, Randomized, Placebo-Controlled Pilot Trial
Diabetes Obes Metab 2021 Jan 19;[EPub Ahead of Print], J Harreiter, I Just, M Leutner, M Bastian, H Brath, C Schelkshorn, R Klepochova, M Krššák, A Kautzky-Willer

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading